- Home
- IMRX vs ADAP Comparison
IMRX vs ADAP Comparison
Compare IMRX & ADAP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMRX
- ADAP
- Stock Information
- Founded
- IMRX 2008
- ADAP 2008
- Country
- IMRX United States
- ADAP United Kingdom
- Employees
- IMRX N/A
- ADAP N/A
- Industry
- IMRX Biotechnology: Pharmaceutical Preparations
- ADAP Biotechnology: Pharmaceutical Preparations
- Sector
- IMRX Health Care
- ADAP Health Care
- Exchange
- IMRX Nasdaq
- ADAP Nasdaq
- Market Cap
- IMRX 62.7M
- ADAP 71.6M
- IPO Year
- IMRX 2021
- ADAP 2015
- Fundamental
- Price
- IMRX $1.64
- ADAP $0.21
- Analyst Decision
- IMRX Strong Buy
- ADAP Strong Buy
- Analyst Count
- IMRX 3
- ADAP 5
- Target Price
- IMRX $11.00
- ADAP $1.93
- AVG Volume (30 Days)
- IMRX 192.2K
- ADAP 2.4M
- Earning Date
- IMRX 03-20-2025
- ADAP 03-20-2025
- Dividend Yield
- IMRX N/A
- ADAP N/A
- EPS Growth
- IMRX N/A
- ADAP N/A
- EPS
- IMRX N/A
- ADAP N/A
- Revenue
- IMRX N/A
- ADAP $178,032,000.00
- Revenue This Year
- IMRX N/A
- ADAP N/A
- Revenue Next Year
- IMRX N/A
- ADAP $56.87
- P/E Ratio
- IMRX N/A
- ADAP N/A
- Revenue Growth
- IMRX N/A
- ADAP 195.34
- 52 Week Low
- IMRX $1.00
- ADAP $0.20
- 52 Week High
- IMRX $3.83
- ADAP $1.55
- Technical
- Relative Strength Index (RSI)
- IMRX 46.94
- ADAP 14.09
- Support Level
- IMRX $1.60
- ADAP $0.26
- Resistance Level
- IMRX $1.91
- ADAP $0.47
- Average True Range (ATR)
- IMRX 0.11
- ADAP 0.04
- MACD
- IMRX 0.02
- ADAP -0.02
- Stochastic Oscillator
- IMRX 44.90
- ADAP 1.23
About IMRX Immuneering Corporation
Immuneering Corp is a biopharmaceutical company. It is focused on improving patient outcomes across a spectrum of debilitating oncologic and neurologic diseases by applying deep knowledge of translational bioinformatics to every stage of the drug development process. The company's proprietary computational Disease Cancelling Technology platform enables Immuneering's drug discovery programs. The company also provides unparalleled computational biology capabilities to pharmaceutical and biotechnology companies.
About ADAP Adaptimmune Therapeutics plc
Adaptimmune Therapeutics PLC is a clinical-stage biopharmaceutical company. It focused on providing novel cell therapies to patients, particularly in solid tumors. It has developed a comprehensive proprietary platform that enables it to identify cancer targets, find and genetically engineer T-cell receptors, and produce TCR therapeutic candidates for administration to patients. Its programs include MAGE-A4 SPEAR T-cell therapy, NY-ESO SPEAR T-cell, CD70 and others for multiple cancer types.